InMed Pharmaceuticals Inc (INM)

[lesgetrich]

A multi dollar share price is certainly a reasonable expectation if their drugs prove to be successful. Here's some info from the Investor Presentation on their epidermolysis bullosa (EB) drug INM-750...

InMed Investor Presentation

- 500 000 patients Globally
- 100,000 patients in Top 10 markets
- 25,000 - 50,000 patients in the US

Cost of Current Therapies for Dermal Applications and Orphan Diseases

• Current standard of care for EB costs $10-15,000 month, or $120-180,000/yr.
• Costs for novel therapies for orphan diseases typically range
from $100,000 to $400,000/yr.


FDA Priority Review Voucher

• Orphan pediatric development program may qualify IN-750 for a transferable FDA priority review voucher
• The most recent priority review voucher sold to AbbVie for US $350 million
• Leerink Partners research predicted the next PRV could fetch US$450- $700m

Company Benchmark

• Scioderm is a U.S. based biotech whose sole clinical
asset is a product in phase 3 clinical trials for EB
• Scioderm was acquired by Amicus for US $847 million
($229 m upfront, plus earn outs based on clinical and regulatory milestones )

- Acquisition was based on results from 42 patients in a phase 2b study
- InMed estimates initiating our phase 2b study by Q2, 2017

Amicus, using third party research, estimated the market for their EB product to be $1 billion+

Their second drug in development is INM-085 and is targeted at Glaucoma...

• 2.7 million people in the United States suffer from glaucoma, a number that is expected to reach 4.3 million by 2030. Globally this number is projected to grow from its current 60 million to 80 million by 2020.

• Glaucoma is the largest drugs segment in global ophthalmic market @
$5.6B globally